Scientific understanding of the mesenchymal stem cell (MSC) secretome continues to evolve, raising important questions about its diverse components and the complexity of these biological systems.
Educational webinar with Tim Moseley, PhD, Chief Scientific Officer at Direct Biologics.
Join Tim Moseley, PhD, Chief Scientific Officer at Direct Biologics, for an educational webinar examining current scientific perspectives on MSC secretome research.
This webinar is intended for educational purposes and will focus on the evolving scientific landscape surrounding MSC secretome research.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.